U.S. Influenza (Flu) Vaccines Market – Growth, Demand, Trends, Opportunity, Forecasts (2021 – 2028)
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
The United States influenza vaccines market size to cross US$ 5.5 Billion by 2028.
This new market report presents an inclusive study of the entire United States influenza vaccines market. The report offers the most uptodate industry data on the actual market situation and future outlook for the United States influenza vaccines market. The report also provides uptodate market size data for the period 2015 2020 and an illustrative forecast to 2028 covering key market aspects like market value and volume for influenza vaccines.
Some of the Major Factors Contributing to the Growth of the Market:
The Surge in the COVID19 Pandemic
Increased Disease Awareness
Introduction of the Quadrivalent Influenza Vaccines
Increasing Research and Development
Expanded Recommendations by Governmental and Advisory Bodies to be Vaccinated against Influenza Vaccines
Key Highlights:
The United States Rises to Become Largest Influenza Vaccines Market
The Demand for the Flu Vaccine is Expected to Increase in the Forecast Period Because of the COVID19 Pandemic Surge
EpiVax to Design Antigens for NextGeneration Flu Vaccine
Versatope Therapeutics, Inc Awarded a Contract worth up to US$17.9 Million from the National Institute of Allergy and Infectious Diseases (NIAID)
This Comprehensive U.S Influenza Vaccines Report Provides:
The Market Size of the United States Influenza Vaccines Market with Seven Years Forecast
Evaluates the United States Overall Persons Being Vaccinated with Influenza Vaccines with Seven Years Forecast
Scrutinizes the United States Children Being Vaccinated with Influenza Vaccines with Seven Years Forecast
Studies the United States Adults Being Vaccinated with Influenza Vaccines with Seven Years Forecast
Delivers Comprehensive Insights on the Latest Pricing Trends and Analysis
Covers a Broad Analysis of the US Influenza Vaccines Production, Supply, and Allocation (By Companies)
Delivers a Complete Outline of the US Influenza Vaccines Distribution and Demand
Studies the Latest Effectiveness of the Influenza Vaccines in the United States
Thoroughly Assessment of the Rapid Diagnostic Testing for the Management of Influenza
Meticulously Assesses of the Distribution Channel and Technique of the Influenza Vaccination in the United States
Detailed Insights into the Regulatory Framework of the United States Influenza Vaccines Market
Features Reimbursement Patterns of the United States Influenza Vaccines Market
Tracks Competitive Developments, Approaches, Recent Industry Developments, Mergers & Acquisitions. Collaboration, Distribution, Exclusive, and Licensing Agreement
An Insightful Investigation has been done on Promising Influenza Vaccines in the Clinical Development
Analyses the Most Recent Clinical Trials of the Influenza Vaccines between 2019 and 2020
Delivers an InDepth Analysis of Evolving Market Trends, Drivers, and Restraints of the United States Influenza Vaccines Market
A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolio, Promising Vaccines in the Clinical Development, Influenza Vaccines Market Value, and Recent Development
An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development
The Key and Emerging Market Players for the U.S Influenza Vaccines Market are Listed Below :
Sanofi Pasteur
GlaxoSmithKline (GSK)
Seqirus (CSL Limited)
AstraZeneca
EpiVax, Inc
Novavax
Medicago
Moderna Inc
Pneumagen
DaiichiSankyo
Altimmune
FluGen
Imutex
Versatope Therapeutics, Inc
BiondVax Pharmaceuticals Ltd.
Key Questions Answered in this Report:
What is the current scenario of the U.S. influenza vaccines market?
What is the total market size and forecast (until 2028) for the U.S. influenza vaccines market?
How many persons being vaccinated with influenza vaccines in the US during 2015 2028?
How effective is influenza(flu) shot for 2020?
What percentage of the United States do people get the flu vaccine?
What are the key marketed influenza vaccines available in the United States?
What are the major drivers of the United States influenza vaccines market?
What are the major inhibitors of the United States influenza vaccines market?
What is the reimbursement pattern in the United States influenza vaccines market?
What is the regulatory framework in the United States influenza vaccines market?
What are the major deals and agreement happenings in the United States influenza vaccines market?
What are the upcoming influenza vaccines that will have a significant impact on the market in the future?
Who are the top market players? What are their happenings, vaccine revenue, current developments, and scenarios?
Who are the emerging players? What are their happenings, clinical development, platform technology, phase, and current developments?
How is the market predicted to develop in the future?
This new market report presents an inclusive study of the entire United States influenza vaccines market. The report offers the most uptodate industry data on the actual market situation and future outlook for the United States influenza vaccines market. The report also provides uptodate market size data for the period 2015 2020 and an illustrative forecast to 2028 covering key market aspects like market value and volume for influenza vaccines.
Some of the Major Factors Contributing to the Growth of the Market:
The Surge in the COVID19 Pandemic
Increased Disease Awareness
Introduction of the Quadrivalent Influenza Vaccines
Increasing Research and Development
Expanded Recommendations by Governmental and Advisory Bodies to be Vaccinated against Influenza Vaccines
Key Highlights:
The United States Rises to Become Largest Influenza Vaccines Market
The Demand for the Flu Vaccine is Expected to Increase in the Forecast Period Because of the COVID19 Pandemic Surge
EpiVax to Design Antigens for NextGeneration Flu Vaccine
Versatope Therapeutics, Inc Awarded a Contract worth up to US$17.9 Million from the National Institute of Allergy and Infectious Diseases (NIAID)
This Comprehensive U.S Influenza Vaccines Report Provides:
The Market Size of the United States Influenza Vaccines Market with Seven Years Forecast
Evaluates the United States Overall Persons Being Vaccinated with Influenza Vaccines with Seven Years Forecast
Scrutinizes the United States Children Being Vaccinated with Influenza Vaccines with Seven Years Forecast
Studies the United States Adults Being Vaccinated with Influenza Vaccines with Seven Years Forecast
Delivers Comprehensive Insights on the Latest Pricing Trends and Analysis
Covers a Broad Analysis of the US Influenza Vaccines Production, Supply, and Allocation (By Companies)
Delivers a Complete Outline of the US Influenza Vaccines Distribution and Demand
Studies the Latest Effectiveness of the Influenza Vaccines in the United States
Thoroughly Assessment of the Rapid Diagnostic Testing for the Management of Influenza
Meticulously Assesses of the Distribution Channel and Technique of the Influenza Vaccination in the United States
Detailed Insights into the Regulatory Framework of the United States Influenza Vaccines Market
Features Reimbursement Patterns of the United States Influenza Vaccines Market
Tracks Competitive Developments, Approaches, Recent Industry Developments, Mergers & Acquisitions. Collaboration, Distribution, Exclusive, and Licensing Agreement
An Insightful Investigation has been done on Promising Influenza Vaccines in the Clinical Development
Analyses the Most Recent Clinical Trials of the Influenza Vaccines between 2019 and 2020
Delivers an InDepth Analysis of Evolving Market Trends, Drivers, and Restraints of the United States Influenza Vaccines Market
A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolio, Promising Vaccines in the Clinical Development, Influenza Vaccines Market Value, and Recent Development
An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development
The Key and Emerging Market Players for the U.S Influenza Vaccines Market are Listed Below :
Sanofi Pasteur
GlaxoSmithKline (GSK)
Seqirus (CSL Limited)
AstraZeneca
EpiVax, Inc
Novavax
Medicago
Moderna Inc
Pneumagen
DaiichiSankyo
Altimmune
FluGen
Imutex
Versatope Therapeutics, Inc
BiondVax Pharmaceuticals Ltd.
Key Questions Answered in this Report:
What is the current scenario of the U.S. influenza vaccines market?
What is the total market size and forecast (until 2028) for the U.S. influenza vaccines market?
How many persons being vaccinated with influenza vaccines in the US during 2015 2028?
How effective is influenza(flu) shot for 2020?
What percentage of the United States do people get the flu vaccine?
What are the key marketed influenza vaccines available in the United States?
What are the major drivers of the United States influenza vaccines market?
What are the major inhibitors of the United States influenza vaccines market?
What is the reimbursement pattern in the United States influenza vaccines market?
What is the regulatory framework in the United States influenza vaccines market?
What are the major deals and agreement happenings in the United States influenza vaccines market?
What are the upcoming influenza vaccines that will have a significant impact on the market in the future?
Who are the top market players? What are their happenings, vaccine revenue, current developments, and scenarios?
Who are the emerging players? What are their happenings, clinical development, platform technology, phase, and current developments?
How is the market predicted to develop in the future?
TABLE OF CONTENTS
1. Executive Summary
2. United States Influenza Vaccines Market Size and Forecasts (2015 2028)
3. United States Number of Persons Vaccinated with Influenza Vaccines (2015 2028)
3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines
4. Key Drivers and Inhibitors of the United States Influenza Vaccines Market
4.1 Market Drivers
4.2 Market Restraints
5. United States Influenza Vaccines Pricing Trends & Analysis
6. United States Influenza Vaccines Production, Supply, and Allocation (By Companies)
7. United States Influenza Vaccines Distribution & Demand (2010 2021)
8. Effectiveness of Influenza Vaccines in the United States (2004 2021)
9. Rapid Diagnostic Testing for the Management of Influenza
10. Distribution Channel and Technique of Influenza Vaccination in the United States
11. Reimbursement Environment of the United States Influenza Vaccines Market
12. Regulatory Framework of the United States Influenza Vaccines Market
13. Major Deals and Agreement Happenings in the Influenza Vaccines Market
13.1 Merger & Acquisitions
13.2 Collaboration Deal
13.3 Licensing Agreement
13.4 Exclusive Agreement
13.5 Distribution Agreement
14. Promising Influenza Vaccines in the Clinical Development
15. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
15.1 Year 2020
15.2 Year 2019
16. Key Players Analysis
16.1 Sanofi Pasteur
16.1.1 Business Overview
16.1.2 Influenza Vaccines Portfolio
16.1.3 Influenza Vaccines Sales Value Analysis
16.1.4 Promising Influenza Vaccines in the Clinical Development
16.1.5 Recent Development
16.2 GlaxoSmithKline (GSK)
16.2.1 Business Overview
16.2.2 Influenza Vaccines Portfolio
16.2.3 Influenza Vaccines Sales Value Analysis
16.2.4 Recent Development
16.3 Seqirus
16.3.1 Business Overview
16.3.2 Influenza Vaccines Portfolio
16.3.3 Influenza Vaccines Sales Value Analysis
16.3.4 Promising Influenza Vaccines in the Clinical Development
16.3.5 Recent Development
16.4 AstraZeneca
16.4.1 Business Overview
16.4.2 Influenza Vaccines Portfolio
16.4.3 Influenza Vaccines Sales Value Analysis
16.4.4 Recent Development
17. Emerging Players
17.1 Novavax
17.1.1 Business Overview
17.1.2 Promising Influenza Vaccines in the Clinical Development
17.1.3 Recent Development
17.2 BiondVax Pharmaceuticals Ltd.
17.2.1 Business Overview
17.2.2 Promising Influenza Vaccines in the Clinical Development
17.2.3 Recent Development
17.3 Medicago
17.3.1 Business Overview
17.3.2 Promising Influenza Vaccines in the Clinical Development
17.3.3 Recent Development
17.4 Moderna Inc
17.4.1 Business Overview
17.4.2 Promising Influenza Vaccines in the Clinical Development
17.4.3 Recent Development
17.5 Pneumagen
17.5.1 Business Overview
17.5.2 Promising Influenza Vaccines in the Clinical Development
17.5.3 Recent Development
17.6 Altimmune
17.6.1 Business Overview
17.6.2 Promising Influenza Vaccines in the Clinical Development
17.6.3 Recent Development
17.7 Daiichi Sankyo
17.7.1 Business Overview
17.7.2 Promising Influenza Vaccines in the Clinical Development
17.7.3 Recent Development
17.8 FluGen
17.8.1 Business Overview
17.8.2 Promising Influenza Vaccines in the Clinical Development
17.8.3 Recent Development
17.9 Imutex
17.9.1 Business Overview
17.9.2 Promising Vaccines in the Clinical Development
17.9.3 Recent Development
17.10 EpiVax
17.10.1 Business Overview
17.10.2 Promising Influenza Vaccines in the Clinical Development
17.10.3 Recent Development
17.11 Versatope Therapeutics, Inc
17.11.1 Business Overview
17.11.2 Promising Influenza Vaccines in the Clinical Development
17.11.3 Recent Development
Table 51: United States Pediatric Influenza Vaccines Price, 2021 2022
Table 52: United States Adult Influenza Vaccine Price, 2021 2022
Table 61: United States Influenza Vaccines Production, Supply, and Allocation
Table 71: Total Percentage of Influenza Vaccines Released by Week, 2020 2021
Table 72: Total Percentage of Influenza Vaccines Released by Week, 2019 2020
Table 73: Total Percentage of Influenza Vaccines Released by Week,2018 2019
Table 74: Total Percentage of Influenza Vaccines Released by Week,2017 2018
Table 75: Total Percentage of Influenza Vaccines Released by Week,2016 2017
Table 76: Total Percentage of Influenza Vaccines Released by Week,2015 2016
Table 77: Total Percentage of Influenza Vaccines Released by Week,2014 2015
Table 81: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 2021
Table 91: Influenza Virus Testing Methods
Table 101: Distribution of Influenza Vaccination
Table 121: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 131: Merger & Acquisitions in the Influenza Vaccines Market
Table 132: Collaboration Deal in the Influenza Vaccines Market
Table 133: Licensing Agreement in the Influenza Vaccines Market
Table 134: Exclusive Agreement in the Influenza Vaccines Market
Table 135: Distribution Agreement in the Influenza Vaccines Market
Table 141: BiondVax Pharmaceuticals Ltd. Clinical Trials
Table 161: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 162: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 171: Novavax Promising Influenza Vaccines in the Clinical Development
Table 172: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 173: Medicago Promising Influenza Vaccines in the Clinical Development
Table 174: Moderna Promising Influenza Vaccines in the Clinical Development
Table 175: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 176: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 177: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 178: FluGen Promising Influenza Vaccines in the Clinical Development
Table 179: Imutex Promising Influenza Vaccines in the Clinical Development
Table 1210: EpiVax Promising Influenza Vaccines in the Clinical Development
Table 1211: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development
Figure 21: United States Influenza Vaccines Market (Million US$),2015 2020
Figure 22: United States Influenza Vaccines Market Forecast (Million US$),2021 2028
Figure 31: United States Total Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 2020
Figure 32: United States Total Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 2028
Figure 33: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2015 2020
Figure 34: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2021 2028
Figure 35: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2015 2020
Figure 36: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2021 2028
Figure 71: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 2021
Figure 101: United States Place of Influenza Vaccination for Children and Adults (Percent),2019 2020
Figure 161: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2015 2020
Figure 162: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2021 2028
Figure 163: GSK Influenza Vaccines Net Sales Value (Million US$),2015 2020
Figure 164: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2021 2028
Figure 165: Seqirus Influenza Vaccines Net Sales Value (Million US$),2015 2020
Figure 166: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2021 2028
Figure 167: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2015 2020
Figure 168: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2021 2028
2. United States Influenza Vaccines Market Size and Forecasts (2015 2028)
3. United States Number of Persons Vaccinated with Influenza Vaccines (2015 2028)
3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines
4. Key Drivers and Inhibitors of the United States Influenza Vaccines Market
4.1 Market Drivers
4.2 Market Restraints
5. United States Influenza Vaccines Pricing Trends & Analysis
6. United States Influenza Vaccines Production, Supply, and Allocation (By Companies)
7. United States Influenza Vaccines Distribution & Demand (2010 2021)
8. Effectiveness of Influenza Vaccines in the United States (2004 2021)
9. Rapid Diagnostic Testing for the Management of Influenza
10. Distribution Channel and Technique of Influenza Vaccination in the United States
11. Reimbursement Environment of the United States Influenza Vaccines Market
12. Regulatory Framework of the United States Influenza Vaccines Market
13. Major Deals and Agreement Happenings in the Influenza Vaccines Market
13.1 Merger & Acquisitions
13.2 Collaboration Deal
13.3 Licensing Agreement
13.4 Exclusive Agreement
13.5 Distribution Agreement
14. Promising Influenza Vaccines in the Clinical Development
15. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
15.1 Year 2020
15.2 Year 2019
16. Key Players Analysis
16.1 Sanofi Pasteur
16.1.1 Business Overview
16.1.2 Influenza Vaccines Portfolio
16.1.3 Influenza Vaccines Sales Value Analysis
16.1.4 Promising Influenza Vaccines in the Clinical Development
16.1.5 Recent Development
16.2 GlaxoSmithKline (GSK)
16.2.1 Business Overview
16.2.2 Influenza Vaccines Portfolio
16.2.3 Influenza Vaccines Sales Value Analysis
16.2.4 Recent Development
16.3 Seqirus
16.3.1 Business Overview
16.3.2 Influenza Vaccines Portfolio
16.3.3 Influenza Vaccines Sales Value Analysis
16.3.4 Promising Influenza Vaccines in the Clinical Development
16.3.5 Recent Development
16.4 AstraZeneca
16.4.1 Business Overview
16.4.2 Influenza Vaccines Portfolio
16.4.3 Influenza Vaccines Sales Value Analysis
16.4.4 Recent Development
17. Emerging Players
17.1 Novavax
17.1.1 Business Overview
17.1.2 Promising Influenza Vaccines in the Clinical Development
17.1.3 Recent Development
17.2 BiondVax Pharmaceuticals Ltd.
17.2.1 Business Overview
17.2.2 Promising Influenza Vaccines in the Clinical Development
17.2.3 Recent Development
17.3 Medicago
17.3.1 Business Overview
17.3.2 Promising Influenza Vaccines in the Clinical Development
17.3.3 Recent Development
17.4 Moderna Inc
17.4.1 Business Overview
17.4.2 Promising Influenza Vaccines in the Clinical Development
17.4.3 Recent Development
17.5 Pneumagen
17.5.1 Business Overview
17.5.2 Promising Influenza Vaccines in the Clinical Development
17.5.3 Recent Development
17.6 Altimmune
17.6.1 Business Overview
17.6.2 Promising Influenza Vaccines in the Clinical Development
17.6.3 Recent Development
17.7 Daiichi Sankyo
17.7.1 Business Overview
17.7.2 Promising Influenza Vaccines in the Clinical Development
17.7.3 Recent Development
17.8 FluGen
17.8.1 Business Overview
17.8.2 Promising Influenza Vaccines in the Clinical Development
17.8.3 Recent Development
17.9 Imutex
17.9.1 Business Overview
17.9.2 Promising Vaccines in the Clinical Development
17.9.3 Recent Development
17.10 EpiVax
17.10.1 Business Overview
17.10.2 Promising Influenza Vaccines in the Clinical Development
17.10.3 Recent Development
17.11 Versatope Therapeutics, Inc
17.11.1 Business Overview
17.11.2 Promising Influenza Vaccines in the Clinical Development
17.11.3 Recent Development
List Of Tables
List of Tables:Table 51: United States Pediatric Influenza Vaccines Price, 2021 2022
Table 52: United States Adult Influenza Vaccine Price, 2021 2022
Table 61: United States Influenza Vaccines Production, Supply, and Allocation
Table 71: Total Percentage of Influenza Vaccines Released by Week, 2020 2021
Table 72: Total Percentage of Influenza Vaccines Released by Week, 2019 2020
Table 73: Total Percentage of Influenza Vaccines Released by Week,2018 2019
Table 74: Total Percentage of Influenza Vaccines Released by Week,2017 2018
Table 75: Total Percentage of Influenza Vaccines Released by Week,2016 2017
Table 76: Total Percentage of Influenza Vaccines Released by Week,2015 2016
Table 77: Total Percentage of Influenza Vaccines Released by Week,2014 2015
Table 81: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 2021
Table 91: Influenza Virus Testing Methods
Table 101: Distribution of Influenza Vaccination
Table 121: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 131: Merger & Acquisitions in the Influenza Vaccines Market
Table 132: Collaboration Deal in the Influenza Vaccines Market
Table 133: Licensing Agreement in the Influenza Vaccines Market
Table 134: Exclusive Agreement in the Influenza Vaccines Market
Table 135: Distribution Agreement in the Influenza Vaccines Market
Table 141: BiondVax Pharmaceuticals Ltd. Clinical Trials
Table 161: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 162: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 171: Novavax Promising Influenza Vaccines in the Clinical Development
Table 172: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 173: Medicago Promising Influenza Vaccines in the Clinical Development
Table 174: Moderna Promising Influenza Vaccines in the Clinical Development
Table 175: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 176: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 177: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 178: FluGen Promising Influenza Vaccines in the Clinical Development
Table 179: Imutex Promising Influenza Vaccines in the Clinical Development
Table 1210: EpiVax Promising Influenza Vaccines in the Clinical Development
Table 1211: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development
List Of Figures
List of Figures:Figure 21: United States Influenza Vaccines Market (Million US$),2015 2020
Figure 22: United States Influenza Vaccines Market Forecast (Million US$),2021 2028
Figure 31: United States Total Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2015 2020
Figure 32: United States Total Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2021 2028
Figure 33: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2015 2020
Figure 34: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2021 2028
Figure 35: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2015 2020
Figure 36: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2021 2028
Figure 71: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 2021
Figure 101: United States Place of Influenza Vaccination for Children and Adults (Percent),2019 2020
Figure 161: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2015 2020
Figure 162: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2021 2028
Figure 163: GSK Influenza Vaccines Net Sales Value (Million US$),2015 2020
Figure 164: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2021 2028
Figure 165: Seqirus Influenza Vaccines Net Sales Value (Million US$),2015 2020
Figure 166: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2021 2028
Figure 167: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2015 2020
Figure 168: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2021 2028
RELATED REPORTS
U.S. Hemostasis Analyzers Reagents Chromogenic Immunodiagnostic
2024 U.S. Hemostasis Analyzers and Reagents--Chromogenic, Immunodiagnostic, Molecular Coagulation Test Volume and Sales Segment Forecasts for Hospitals, Commercial/Private Labs and POC Locations--2023 Competitive Shares and Growth Strategies, Latest Technologies and
View ReportU.S. Coagulation Testing Shares Competitive
2024 U.S. Coagulation Testing Market Shares--Competitive Analysis of Leading and Emerging Market Players This new report provides coagulation testing market shares.The report analyzes current and emerging suppliers of coagulation testing
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
